Revance Announces Closing of Public Offering of Common Stock
December 11 2017 - 4:05PM
Business Wire
Gross Proceeds of Offering Total $167.1
Million
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology
company developing botulinum toxin products for use in treating
aesthetic and therapeutic conditions (“Revance” or the “Company”),
today announced the closing of an underwritten public offering of
6,139,515 shares of its common stock at a price to the public of
$31.00 per share. In the offering, the Company issued and sold
5,389,515 shares, including the exercise in full by the
underwriters of their option to purchase 550,806 additional shares
of common stock from the Company, and certain stockholders of the
Company (the “Selling Stockholders”) sold 750,000 shares, including
the exercise in full by the underwriters of their option to
purchase 250,000 additional shares of common stock from the Selling
Stockholders. The gross proceeds to the Company from the offering,
before deducting the underwriters’ discounts and other estimated
offering expense payable by the Company, were approximately $167.1
million. The Company did not receive any proceeds from the sale of
the shares by the Selling Stockholders.
Goldman Sachs & Co. LLC and Cowen acted as book-running
managers, Barclays acted as joint lead manager, and Cantor
Fitzgerald & Co., William Blair & Company, L.L.C. and
SunTrust Robinson Humphrey acted as co-managers for the
offering.
A shelf registration statement relating to the securities
described above was filed with the Securities and Exchange
Commission on December 5, 2017 and automatically became effective
the same day. The offering was made only by means of a prospectus
supplement. Copies of the final prospectus supplement and
accompanying prospectus relating to the public offering may be
obtained by contacting Goldman Sachs & Co. LLC, Prospectus
Department, 200 West Street, New York, NY 10282, telephone:
1-866-471-2526, facsimile: 212-902-9316 or by emailing
Prospectus-ny@ny.email.gs.com; or Cowen and Company, LLC, c/o
Broadridge Financial Services, Attention: Prospectus Department,
1155 Long Island Avenue, Edgewood, NY 11717, Telephone:
631-274-2806, Fax: 631-254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a clinical-stage biotechnology company focused on the
development, manufacturing, and commercialization of novel
botulinum toxin products for multiple aesthetic and therapeutic
indications. Revance is leveraging its proprietary portfolio of
botulinum toxin type A compounds, formulated with its patented and
proprietary peptide technology, to address unmet needs in large and
growing neurotoxin markets.
"Revance Therapeutics" and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171211005692/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami
Bavishi, 212-213-0006abavishi@burnsmc.comorMEDIAGeneral
Media:TOGORUN:Mariann Caprino,
917-242-1087m.caprino@togorun.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024